What do systematic reviews say?

Acupressure vs placebo or control

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 459 participants
  Low

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupressure vs placebo or control

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aromatherapy vs placebo or usual care

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 542 participants
  Low

Aromatherapy vs placebo or usual care

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aromatherapy vs placebo or usual care

The review found no eligible studies for this question.

• Interventions for fatigue in people with kidney failure requiring dialysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Erythromycin vs placebo

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 255 participants
  Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

It is very uncertain whether erythromycin plus nasogastric tube lavage changes all‐cause mortality compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 238 participants
  Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 170 participants
  Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

It is very uncertain whether erythromycin plus nasogastric tube lavage changes NSAEs compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  RD 0
  6 studies · 408 participants
  Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

It is very uncertain whether erythromycin plus nasogastric tube lavage changes rebleeding compared with no intervention/placebo plus nasogastric tube lavage (very low certainty).

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  RR 1.13 [0.63, 2.02]
  1 study · 169 participants
  Very low

Erythromycin plus nasogastric tube lavage vs no intervention/placebo plus nasogastric tube lavage

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 180 participants
  Very low

Erythromycin vs placebo

It is very uncertain whether erythromycin changes SAEs compared with placebo (very low certainty).

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 255 participants
  Very low

Erythromycin vs placebo

It is very uncertain whether erythromycin changes all‐cause mortality compared with placebo (very low certainty).

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  RD 0
  3 studies · 255 participants
  Very low

Erythromycin vs placebo

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 195 participants
  Low

Erythromycin vs placebo

It is very uncertain whether erythromycin changes NSAEs compared with placebo (very low certainty).

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  RD 0.01
  3 studies · 255 participants
  Very low

Erythromycin vs placebo

It is very uncertain whether erythromycin changes rebleeding compared with placebo (very low certainty).

• Erythromycin prior to endoscopy for acute upper gastrointestinal haemorrhage 2023 · Cochrane Headline outcomes only
  RR 0.63 [0.13, 2.9]
  2 studies · 195 participants
  Very low